Refractory thrombocytopenia after 177Lu-PSMA therapy: bone marrow infiltration (myelophthisis) versus treatment toxicity
DOI:
https://doi.org/10.37609/srinmed.63Anahtar Kelimeler:
Lutetium- Myelophthisis- Prostate cancer- ThrombocytopeniaÖz
Lutetium is a radiopharmaceutical used effectively to treat metastatic castration-resistant prostate cancer (mCRPC). Myelosuppression can occur after lutetium therapy, and it can be difficult to distinguish between treatment-related toxicity and bone marrow infiltration (myelophthisis), especially in patients with extensive bone metastases.
A 60-year-old male patient with metastatic castration-resistant prostate cancer was scheduled for 177Lu-PSMA therapy after progression on docetaxel and abiraterone. Thrombocytopenia developed after the first course. At the same time, the patient developed infective endocarditis. Although platelet counts temporarily improved with infection management, severe thrombocytopenia recurred after the second 177Lu-PSMA cycle.
Bone marrow biopsy revealed infiltration by prostate adenocarcinoma. It was determined that the patient's thrombocytopenia was caused by cancer infiltration of the bone marrow and the resulting myelophthisis.
Hematologic toxicity is a recognized complication of 177Lu-PSMA therapy in patients with mCRPC and extensive skeletal involvement, bone marrow is essential to differentiate between effects caused by treatment and myelophthisis in cases of refractory cytopenia.
İndirmeler
Referanslar
Mones JV, Soff G. Management of thrombocytopenia in cancer patients. Thrombosis and Hemostasis in Cancer. 2019:139-50. https://doi.org/10.1007/978-3-030-20315-3_9
Makoni SN, Laber DA. Clinical spectrum of myelophthisis in cancer patients. American journal of he-matology. 2004;76(1):92-3. https://doi.org/10.1002/ajh.20046
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). American Society of Clinical Oncology; 2022. https://doi.org/10.1200/JCO.2022.40.16_suppl.5000
Morris MJ, De Bono JS, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). American Society of Clinical Oncology; 2021. https://doi.org/10.1200/JCO.2021.39.15_suppl.LBA4
Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O’Sullivan JM, Parker C, et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the AL-SYMPCA trial. Clinical genitourinary cancer. 2017;15(1):42-52. e8. https://doi.org/10.1016/j.clgc.2016.07.027
Groener D, Baumgarten J, Haefele S, Happel C, Klimek K, Mader N, et al. Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement. Cancers. 2021;13(16):4017. https://doi.org/10.3390/cancers13164017
Groener D, Nguyen CT, Baumgarten J, Bockisch B, Davis K, Happel C, et al. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI research. 2021;11(1):61. https://doi.org/10.1186/s13550-021-00805-7
Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, et al. Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study. European Urology. 2020;78(2):148-54. https://doi.org/10.1016/j.eururo.2020.05.004
Ahmadzadehfar H, Matern R, Baum RP, Seifert R, Kessel K, Bögemann M, et al. The impact of the ex-tent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu] Lu-PSMA-617: a WARMTH multicentre study. European Journal of Nuclear Medicine and Molecular Imag-ing. 2021;48(12):4067-76. https://doi.org/10.1007/s00259-021-05383-3
Kind F, Michalski K, Yousefzadeh-Nowshahr E, Meyer PT, Mix M, Ruf J. Bone marrow impairment dur-ing early [177Lu] PSMA-617 radioligand therapy: haematotoxicity or tumour progression? EJNMMI re-search. 2022;12(1):20. https://doi.org/10.1186/s13550-022-00891-1
Kristiansen I, Stephan C, Jung K, Dietel M, Rieger A, Tolkach Y, et al. Sensitivity of HOXB13 as a diag-nostic immunohistochemical marker of prostatic origin in prostate cancer metastases: comparison to PSA, prostein, androgen receptor, ERG, NKX3. 1, PSAP, and PSMA. International journal of molecu-lar sciences. 2017;18(6):1151. https://doi.org/10.3390/ijms18061151
Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, et al. Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and can-cerous tissues. Oncotarget. 2019;10(52):5439. https://doi.org/10.18632/oncotarget.27145
Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. NKX3. 1 as a marker of prostatic origin in metastatic tumors. The American journal of surgical pathology. 2010;34(8):1097-105. https://doi.org/10.1097/PAS.0b013e3181e6cbf3
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the proba-bility of adverse drug reactions. Clinical Pharmacology & Therapeutics. 1981;30(2):239-45. https://doi.org/10.1038/clpt.1981.154
Mangaonkar AA, Gupta HR, Bera BM, Barmare S. Bone marrow fibrosis and metastatic prostate ade-nocarcinoma. BMJ Case Reports CP. 2012;2012:bcr2012007348. https://doi.org/10.1136/bcr-2012-007348
Abou Zahr A, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101(6):660. https://doi.org/10.3324/haematol.2015.141283
İndir
Yayınlanmış
Sayı
Bölüm
Lisans
Telif Hakkı (c) 2026 Scientific Reports in Medicine
Bu çalışma Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License ile lisanslanmıştır.
The Journal and content of this website is licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access. The Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allows users to copy, distribute and transmit unmodified article, and make noncommercial use of the article. The CC BY license permits non-commercial re-use of an open access article, as long as the author is properly attributed.
